Roquefort Therapeutics plc is a material biotech company focused on next generation medicines for hard to treat cancers
2020
Company Founded
5
Pre - Clinical Programs
2021
IPO London Main Market
Regulatory News
Regulatory News
07.11.2024
Conversion of Convertible Loan Notes
06.11.2024
STAT-6 siRNA Presentation
27.09.2024
Interim Results to 30 June 2024
High growth immuno-oncology market
Our Portfolio
Our portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines.
The highly complementary portfolio of best-in-class medicines is focused on the cancers that remain resistant to existing therapies and creates significant upside potential in high value and high growth immuno-oncology market.
Expert team
Leadership
Expert leadership team with proven track record in drug development, regulatory approvals and biotech transactions.
The team includes Nobel Laureate, Professor Sir Martin Evans and experienced biotechnology CEO, Ajan Reginald.
UK location
State of the art facility
Access to state of the art laboratory located in Stratford-upon-Avon that includes a clean room, laminar flow cabinets and cryopreservation infrastructure required for pre-clinical development of innovative new medicines, particularly cell and gene therapies.
Enhanced Network
Partnering
Network of partnerships with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure and enables us to implement a broader and more effective development strategy.
This distributed R&D model is highly scalable and cost effective.